Sandbox southuniversity6: Difference between revisions
Arthur Cox (talk | contribs) No edit summary |
Arthur Cox (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
The functional groups proposed for the [[pharmacophore]] of the DKAs includes a aromatic ring located a certain distance from hydrogen bond donating and accepting groups. Looking at the enol tautomer of L-731,988, how many hydrogen bond donors do you see? | The functional groups proposed for the [[pharmacophore]] of the DKAs includes a aromatic ring located a certain distance from hydrogen bond donating and accepting groups. Looking at the enol tautomer of L-731,988, how many hydrogen bond donors do you see? | ||
[[Image:isentress.png|left|300px|raltegravir (isentress)]] | |||
Compare the structure of raltegravir (Isentress)to that of the prototype DKA shown above. Can you see a hydrophobic group at one end of the molecule, with hydrogen bond donor, acceptor, and donor functional groups next to each other? | |||
<StructureSection load='RLT' size='500' side='right' caption='Structure of the first HIV integrase inhibitor to market, raltegravir (PDB entry [[RLT]])' scene=''>The structure to the left is the first HIV integrase that has made it's way to market, raltegravir (Isentress). | <StructureSection load='RLT' size='500' side='right' caption='Structure of the first HIV integrase inhibitor to market, raltegravir (PDB entry [[RLT]])' scene=''>The structure to the left is the first HIV integrase that has made it's way to market, raltegravir (Isentress). | ||
</StructureSection> | </StructureSection> | ||